{"entity":{"id":"nct06343311","kind":"trial","name":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","aka":[],"tldr":"A phase 1/2 trial of EB103 in non-Hodgkin lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma, run by Estrella Biopharma, Inc., now recruiting.","summary":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) is a phase 1/2 interventional study registered as NCT06343311 by Estrella Biopharma, Inc., with 21 participants planned, started 2024-06-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: EB103.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06343311","url":"https://clinicaltrials.gov/study/NCT06343311"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06343311","phase":"1/2","setting":"An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)","sponsor":"Estrella Biopharma, Inc.","enrolled":21,"outcomes":[]},"route":"/trials/nct06343311/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}